- Earn 4.5% interest on uninvested cash with Gold
- Get up to $50,000 in instant deposits with Gold
- Easy, user-friendly trading
- Unlimited bonus amounts Oct 16-27
Tekmira Pharmaceuticals Corporation is an other business based in the US. Tekmira Pharmaceuticals Corporation shares (TKMR) are listed on the NASDAQ and all prices are listed in US Dollars. Tekmira Pharmaceuticals Corporation employs 0 staff and has a market cap (total outstanding shares value) of 0.00.
Our top picks for where to buy Tekmira Pharmaceuticals Corporation stock
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Tekmira Pharmaceuticals Corporation stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – TKMR. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Tekmira Pharmaceuticals Corporation stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Tekmira Pharmaceuticals Corporation stock price (NASDAQ: TKMR)
Use our graph to track the performance of TKMR stocks over time.Tekmira Pharmaceuticals Corporation shares at a glance
52-week range | $0.00 - $0.00 |
---|---|
50-day moving average | $10.83 |
200-day moving average | $10.83 |
Wall St. target price | N/A |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | N/A |
Is it a good time to buy Tekmira Pharmaceuticals Corporation stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Tekmira Pharmaceuticals Corporation financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | 0% |
Return on equity TTM | 0% |
Profit margin | 0% |
Book value | N/A |
Market Capitalization | $156.2 million |
TTM: trailing 12 months
Tekmira Pharmaceuticals Corporation share dividends
We're not expecting Tekmira Pharmaceuticals Corporation to pay a dividend over the next 12 months.
Tekmira Pharmaceuticals Corporation overview
DELISTED - Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners. On March 1, 2012, it announced that the Company had secured a license from Alnylam to develop TKMALDH2, an RNAi therapeutic that utilizes Tekmira's LNP for the treatment of Alcohol Dependence (AD). Its lead oncology product candidate, TKM-PLK1, targets PLK1, a protein involved in tumor cell proliferation and a validated oncology target. On February 8, 2012, it announced that Phase I clinical trial for TKM-Ebola had been initiated. The Phase 1 TKM-Ebola clinical trial is a placebo-controlled, single-blind, single-ascending dose study with additional multiple-ascending dose cohorts in healthy human volunteers. In the field of RNAi therapeutics, the Company has licensed its LNP delivery technology to Alnylam Pharmaceuticals, Inc. and Merck & Co.
Frequently asked questions
How many people work for Tekmira Pharmaceuticals Corporation?Latest data suggests 0 work at Tekmira Pharmaceuticals Corporation. What is Tekmira Pharmaceuticals Corporation's ISIN number?
Tekmira Pharmaceuticals Corporation's international securities identification number is: US03879J1007 What is Tekmira Pharmaceuticals Corporation's CUSIP number?
Tekmira Pharmaceuticals Corporation's Committee on Uniform Securities Identification Procedures number is: 03879J100
More guides on Finder
-
Fundamental Analysis
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
9 Best Discount Brokers of 2024 for Low-Cost Trading
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
eToro review 2024: Commission-free social trading and investing
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
-
How to trade options
Read our beginner’s guide to trading options in the US.
Ask a question